pharmaceuticals
| ‘Blood on Its Hands’: FDA Will Remove Anti-ivermectin Social Media, Website Posts Under Lawsuit Settlement Agreement |
| 2015 Nobel Prize in Physiology or Medicine |
| A Combination of Ivermectin and Doxycycline Possibly Blocks the Viral Entry and Modulate the Innate Immune Response in COVID-19 Patients |
| A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin |
| An overview of the MATH+, I-MASK+ and I-RECOVER Protocols — A Guide to the Management of COVID-19 |
| Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial |
| Canary In a Covid World: How Propaganda and Censorship Changed Our (My) World |
| Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours |
| Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection |
| Coronavirus Disease 2019 (COVID-19) Treatment Guidelines |
| COVID-19 Excess Deaths in Peru’s 25 States in 2020: Nationwide Trends, Confounding Factors, and Correlations With the Extent of Ivermectin Treatment by State |
| COVID-19 Treatment Guidelines |
| COVID-19 Treatment Guidelines - Ivermectin |
| Critical appraisal of multidrug therapy in the ambulatory management of patients with COVID-19 and hypoxemia |
| Critical appraisal of multidrug therapy in the ambulatory management of patients with COVID-19 and hypoxemia Part I. Evidence supporting the strength of association |
| Dr Mike Yeadon Ivermectin Anti-Fertility Bombshell: "One Of The Most Violent Fertility Toxins" |
| Early Ambulatory Multidrug Therapy Reduces Hospitalization and Death in High-Risk Patients with SARS-CoV-2 (COVID-19) |
| Exclusive: What Was It Like Being a ‘Canary In a Covid World’? Doctors, Activists Speak Out |
| Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach |
| FDA tweet on Ivermectin in August 2021 |
| Insights from a computational analysis of the SARS-CoV-2 Omicron variant: Host-pathogen interaction, pathogenicity and possible therapeutics |
| Ivermectin as a Potential Addition to the Limited Anti-COVID-19 Arsenal: A Double-Blinded Clinical Trial |
| Ivermectin as a SARS-CoV-2 Pre-Exposure Prophylaxis Method in Healthcare Workers: A Propensity Score-Matched Retrospective Cohort Study |
| Ivermectin as Prophylaxis Against COVID-19 Retrospective Cases Evaluation |
| Ivermectin Could Have Saved Millions of Lives, Why Was It Suppressed |
| Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes |
| Ivermectin for COVID-19: Real-time meta-analysis of 99 studies |
| Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines |
| Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial |
| Ivermectin prophylaxis used for COVID-19 reduces COVID-19 infection and mortality rates: A 220,517-subject, populational-level retrospective citywide observational study |
| Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching |
| Ivermectin reduces in vivo coronavirus infection in a mouse experimental model |
| Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19 |
| Ivermectin: an award-winning drug with expected antiviral activity against COVID-19 |
| Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection |
| One Page Summary of the Clinical Trials Evidence for Ivermectin in COVID-19 |
| Overseas Refugee Health Guidance |
| Randomized trials - Ivermectin repurposing for COVID-19 treatment of outpatients with mild disease in primary health care centers |
| Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects |
| Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities |
| Results of a systematic review and meta‑analysis of early studies on ivermectin in SARS‑CoV‑2 infection |
| Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 |
| Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study |
| Send This Article to People Who Say “Ivermectin Doesn’t Work for Covid-19” |
| Sharp Reductions in COVID-19 Case Fatalities and Excess Deaths in Peru in Close Time Conjunction, State-By-State, with Ivermectin Treatments |
| Sub-committee hearing on early treatment of COVID-19 - Testimony of Pierre Kory, MD |
| Summary of the Evidence for Ivermectin in COVID-19 |
| The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 – a double-blind, randomized placebo-controlled trial |
| The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |
| The Use of Compassionate Ivermectin in the Management of Symptomatic Outpatients and Hospitalized Patients with Clinical Diagnosis of Covid-19 at the Centro Medico Bournigal and at the Centro Medico Punta Cana, Grupo Rescue, Dominican Republic, fro |
